Also, targeting SOAT1 via avasimibe could enhance the killing effect of CD8 + T cells on melanoma by elevating membrane cholesterol content; thus, promoting T-cell receptor (TCR) aggregation and immune synapse formation13. Here, CD8A is linked to melanoma.